Sonoma Pharmaceuticals Announces Management Changes
01 Oktober 2019 - 11:09PM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty
pharmaceutical Company dedicated to identifying, developing and
commercializing unique, differentiated therapies to millions of
patients living with chronic skin conditions, today announced the
following management changes.
Bubba Sandford left Sonoma on September 25 after nine months as
CEO and Interim CFO after successfully evaluating the Company’s
prospects while substantially reducing its cash burn. Mr.
Sandford will remain on the Board of Directors for six months
following his departure date.
The Board of Directors named Amy Trombly as Sonoma’s Interim
Chief Executive Officer and promoted John Dal Poggetto to Chief
Financial Officer, effective immediately. The Board has begun the
search for a new Chief Executive Officer with deep industry
experience.
Ms. Trombly has served as the Company’s Corporate and Securities
Counsel for over 10 years and has broad knowledge of the Company’s
operations. Mr. Dal Poggetto has served as the Company’s Executive
Vice President of Finance since 2017 and prior to that was the
Company’s Controller since 2002.
Jerry McLaughlin, Sonoma’s Lead Independent Director, said
“Bubba has done an exemplary job in righting the ship. The board
wishes him success in his next assignment as we explore all options
to build shareholder value.” He continued, “the board is confident
that Amy is the correct choice to lead Sonoma during this interim
period and John will bring years of industry knowledge and
financial expertise to facilitate a smooth transition.”
Amy Trombly added “I value the trust placed in me to lead the
Company while the board takes the necessary time to find a CEO with
industry experience.” She continued “I have known John from my work
as counsel for Sonoma for years, and he has proven himself to be an
outstanding financial executive. I look forward to working with him
in the coming months.”
About Amy Trombly
Amy Trombly has counseled public companies for two decades in
corporate and securities law and mergers and acquisitions.
She has owned and managed Trombly Business Law, PC since
2002. In her earlier career, Ms. Trombly was a Vice President
at State Street Bank and Special Counsel at the U.S. Securities and
Exchange Commission. Ms. Trombly is a member of the bar in
Massachusetts and Colorado.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical Company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The Company’s headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “preparing,”
“represent,” and “upcoming,” among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to meet the Company’s cash needs, fund further
development and clinical studies, as well as uncertainties relative
to varying product formulations and a multitude of diverse
regulatory and marketing requirements in different countries and
municipalities, and other risks detailed from time to time in the
Company’s filings with the Securities and Exchange Commission. The
Company disclaims any obligation to update these forward-looking
statements, except as required by law.
Sonoma Pharmaceuticals™ is a trademark or registered trademark
of Sonoma Pharmaceuticals, Inc.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Investor Relations
(925) 787-6218
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Mär 2023 bis Mär 2024